Get started
Author

Sergey G Shchur

Observed names: S G Shchur, S. G. Shchur, S.G. Shchur, Sergei Gennadievich Shchur, Sergey Shchur, С Г Щур, С.Г. Щур
ORCID: 0000-0002-1715-0465
Observed ORCID: 0000-0002-1715-0465
OpenAlex ID: A5041074430
Benefits of eculizumab in AQP4+ neuromyelitis optica spectrum disorder: Subgroup analyses of the randomized controlled phase 3 PREVENT trial
2020 · Jacqueline Palace, Dean M. Wingerchuk, et al. · Multiple Sclerosis and Related Disorders · 46
PDF
Association of SNPs of CD40 Gene with Multiple Sclerosis in Russians
2013 · Ekaterina Alekseevna Sokolova, Nadezhda Alekseevna Malkova, et al. · PLoS ONE · 37
PDF
Allelic Combinations of Immune-Response Genes Associated with Glatiramer Acetate Treatment Response in Russian Multiple Sclerosis Patients
2011 · Ekaterina Y Tsareva, Olga G Kulakova, et al. · Pharmacogenomics · 28
Results of a phase 1 clinical study of anti-CD20 monoclonal antibody (BCD-132): pharmacokinetics, pharmacodynamics and safety
2019 · O.V. Boyko, A.N. Boyko, et al. · S S Korsakov Journal of Neurology and Psychiatry · 22
Allelic Combinations of Immune-Response Genes as Possible Composite Markers of IFN-β Efficacy in Multiple Sclerosis Patients
2012 · Olga G Kulakova, Ekaterina Yu Tsareva, et al. · Pharmacogenomics · 17
Pharmacogenetics of Glatiramer Acetate Therapy for Multiple Sclerosis: the Impact of Genome-Wide Association Studies identified disease risk loci
2017 · Olga Kulakova, Vitalina Bashinskaya, et al. · Pharmacogenomics · 16
Efficacy and safety of antiCD20 monoclonal antibody divozilimab during 48-week treatment of multiple sclerosis patients in randomized double-blind placebo-controlled clinical trial BCD-132-4/MIRANTIBUS
2023 · A.N. Boyko, V.M. Alifirova, et al. · S S Korsakov Journal of Neurology and Psychiatry · 14
Pharmacogenomics of multiple sclerosis: Association of immune response gene polymorphisms with copaxone treatment efficacy
2011 · E. Yu. Tsareva, O. G. Kulakova, et al. · Molecular Biology · 14
Long-term efficacy and safety of divozilimab during 2-year treatment of multiple sclerosis patients in randomized double-blind placebo-controlled clinical trial BCD-132-4/MIRANTIBUS
2024 · A.N. Boyko, V.M. Alifirova, et al. · S S Korsakov Journal of Neurology and Psychiatry · 13
PDF
Efficacy and safety of divozilimab during 24-week treatment of multiple sclerosis patients in randomized double-blind placebo-controlled clinical trial BCD-132-2
2023 · A.N. Boyko, V.M. Alifirova, et al. · S S Korsakov Journal of Neurology and Psychiatry · 13
Efficacy and safety of sampeginterferon β-1a in the treatment of relapsing remitting multiple sclerosis: results of 52 weeks of therapy in a randomized, double-blind clinical trial
2022 · A.N. Boyko, O.V. Boyko, et al. · S S Korsakov Journal of Neurology and Psychiatry · 10
Experience of using interferon β-1a biosimilans (cinnovex and genfaxon-44) in the Moscow Multiple Sclerosis Center
2015 · O. G. Borets, M. V. Davydovskaya, et al. · S S Korsakov Journal of Neurology and Psychiatry · 9
Real-world study of efficacy, risk management and reasons for discontinuation of natalizumab for treatment of multiple sclerosis in Russia
2019 · Evgeniy Evdoshenko, Alexandra Stepanova, et al. · PLoS ONE · 8
PDF
Long-term Efficacy and Safety of Sampeginterferon-β1a in the Treatment of Relapsing Remitting Multiple Sclerosis: a Randomized, Double-Blind Clinical Trial 104-Week Results
2023 · A.N. Boyko, K.Z. Bakhtiyarova, et al. · S S Korsakov Journal of Neurology and Psychiatry · 4
Experience in the Use of the β-Interferon-1a Biosimilars CinnoVex and Genfaxon-44 at the Moscow City Multiple Sclerosis Center
2016 · O. G. Borets, M. V. Davydovskaya, et al. · Neuroscience and Behavioral Physiology · 4
[The first experience of the use the Russian Β-interferon-1b biosimilar (infibeta) in the daily practice of the Moscow Center of Multiple Sclerosis].
2013 · E V Popova, A N Boĭko, et al. · PubMed · 4
[Efficacy and tolerability of long-term using of glatimer acetate (copaxone): a 10 year-study in the Moscow Municipal Multiple Sclerosis center].
2012 · A N Boĭko, M V Davydovskaia, et al. · PubMed · 4
Efficacy and Tolerance of Glatiramer Acid (Copaxone) on Long-Term Use: 10 Years of Experience at the Moscow City Multiple Sclerosis Center
2013 · A. N. Boiko, M. V. Davydovskaya, et al. · Neuroscience and Behavioral Physiology · 3
[The results of longitudinal use of copaxone and betaferon in Moscow Multiple Sclerosis Center: issues of efficacy and adherence to therapy].
2006 · A N Boĭko, M F Davydovskaia, et al. · PubMed · 3
Survey of diagnostic and treatment practices for multiple sclerosis in Russian Federation in comparison to European data
2021 · Alexey Boykо, Oscar Fernández, et al. · Multiple Sclerosis and Related Disorders · 2
[Results of a comparative clinical trial of the Russian Β - interferon-1b bioanalogue (infibeta)].
2012 · E V Popova, A N Boĭko, et al. · PubMed · 2
[The comparative study of efficacy and tolerability of intramuscular introduction of beta-interferon-1a in adults and adolescents with remitting multiple sclerosis].
2012 · A N Boĭko, T T Batysheva, et al. · PubMed · 1
[Data of MRI and neuropsychological tests predict the course of typical remitting multiple sclerosis during five years].
2011 · B T Mugutdinova, A N Boĭko, et al. · PubMed · 1
Финголимод в лечении ремитирующего рассеянного склероза: опыт применения в Московском городском центре рассеянного склероза
2014 · Popova Ev, А А Ялымов, et al. · Meditsinskiy sovet = Medical Council
Анализ ассоциации аллельного полиморфизма гена CTLA4 с предрасположенностью к рассеянному склерозу и с особенностями его клинического течения
2012 · В В Башинская, О. Г. Кулакова, et al. · Вестник Российского государственного медицинского университета
Works count: 30
Citation count: 275
H-index: 10
I10-index: 11
Year
Topic
Type